A Rutgers-led analysis of lemborexant reviews highlights reported side effects, evidence limits and the value of clinician follow-up.
On October 29, 2026, Rutgers University reported on a study published in Sleep Medicine examining online accounts of lemborexant, sold as Dayvigo. Working with colleagues at Virginia Commonwealth University and the University of Sydney, the researchers analyzed 260 reviews posted from 2020 through 2023.
The central finding concerned tolerability: how acceptable a treatment feels to the person using it. The Rutgers-led team classified 70 reviewers as having stopped or planning to stop lemborexant. Reports of sleep paralysis, vivid dreams or nightmares and next-day grogginess featured more often in that group.
Sleep paralysis showed a clear difference within the review sample. Rutgers reported that it appeared in 40% of reviews from people who had stopped or planned to stop treatment. It appeared in 15% of reviews from the remaining reviewers.
The findings also suggested that stopping decisions involved more than whether sleep had improved. Reviewers in the discontinuation group were less likely to say the medicine had helped. Yet complaints about poor or interrupted sleep alone did not clearly distinguish them from the other reviewers.
Across all 260 reviews, Rutgers reported a mixed picture:
These findings place the experience of treatment alongside its intended benefit. A useful follow-up conversation therefore has room for both whether sleep improved and what the person found difficult about taking the medicine. Reporting a benefit and finding an experience unacceptable are separate judgments.
Lead author Abanoub J. Armanious made that distinction in the Rutgers account. He said clinical trials can measure how often an effect occurs but may be less able to capture how much it matters to an individual. A rare effect can still be the reason that person stops treatment.
Senior author Morgan James pointed to the range of reported experiences as a reason to set expectations and find an appropriate treatment for the individual. The practical focus is not simply whether an experience appears on a list of possible effects. It is also how that experience affects the person receiving treatment.
The study’s main limitation belongs beside its findings. Online reviewers select themselves: people with especially positive or negative experiences may be more motivated to post. The researchers could not independently verify every account or establish what caused each reported symptom. These percentages therefore describe this collection of reviews, not the frequency of side effects or discontinuation among everyone taking lemborexant.
Clinical-trial figures provide a different kind of evidence. Rutgers reported that the drug’s two main trials found sleep paralysis in fewer than 2% of participants taking lemborexant. Nightmares or abnormal dreams were reported by about 1% to 3%.
The trial figures and review percentages should not be treated as directly comparable risk estimates. They come from different ways of collecting information. Placing them side by side does not show that the trials were wrong or that the online reviews reveal a hidden population-wide rate.
The reviews also offered a limited view of treatment over time. According to Rutgers, most reviewers had used the medicine for less than a month. This was especially true among those who had stopped or planned to stop. Longer-term users tended to give higher ratings, but the analysis could not explain why.
That last finding is not a reason to advise someone to keep taking a medicine until an unwanted experience passes. It does not establish that continuing treatment will improve tolerability. Decisions about an individual’s treatment belong in a conversation with a clinician.
Rutgers describes lemborexant as blocking orexin signals, which help keep people awake. The university also reported that clinical trials found the medicine helped people fall asleep faster and stay asleep longer than placebo.
The researchers proposed that orexin-blocking medicines could affect dreaming sleep. This might allow dream experiences or the usual muscle shutdown during dreaming to intrude into moments of waking. The explanation is a hypothesis rather than proof of what caused any reviewer’s experience.
Taken together, these boundaries define the study’s contribution. It offers material for understanding what some reviewers found disruptive and what they connected with stopping decisions. Its strongest practical use is to make follow-up conversations more specific, not to supply a new risk calculator.
For an adult aged 35 to 65 balancing work or caring responsibilities, the most useful adjustment is a communication habit rather than a medication change. A brief note about the night and the following day can provide concrete material for discussing treatment with a clinician.
This is a practical way to apply the researchers’ distinction between average benefit and personal impact. It need not become a detailed tracking project or another recovery target. The aim is to describe what happened in words that remain useful at the next appointment.
A note can begin with whether the medicine seemed to help with the problem being discussed in care. Did falling asleep feel easier? Was sleep less interrupted? Was there little noticeable benefit?
These descriptions keep the intended purpose of treatment visible. They also leave room to report a mixed experience: sleep may have seemed better while another part of the night or following day felt worse. There is no need to force the whole experience into a single positive or negative rating.
If vivid dreams, sleep paralysis or grogginess occur, the useful information is what the person experienced and how disruptive it felt. An account might distinguish an unusual dream from an experience that made the night feel distressing. It might also describe whether grogginess interfered with ordinary responsibilities.
The purpose is not to decide independently that the medicine caused the symptom. It is to give the clinician a clear account to assess. A description of the experience and its effect on daily functioning is more informative than a review score alone.
For readers already worrying about the next night’s sleep, this approach keeps the conversation anchored in their own experience. Someone else’s account need not become the script for what they expect to happen.
The Rutgers findings make next-day grogginess part of the follow-up discussion rather than an afterthought. A note can describe whether the person felt able to manage the day’s usual demands. That keeps daytime fatigue and attention in view alongside the nighttime experience.
This is particularly relevant to the question of recovery. An assessment centered only on falling asleep leaves out the reader’s concern about feeling restored. Bringing both parts to an appointment gives the discussion a clearer focus without requiring a complicated monitoring routine.
The researchers’ advice was to speak with a clinician before stopping or changing prescribed sleep medication. Questions about continuing treatment or responding to unwanted effects need individual clinical judgment. The review analysis is a reason to raise those questions, not an instruction to make a change alone.
The American Academy of Sleep Medicine lists separate practice guidelines for pharmacologic treatment and for behavioral and psychological treatment of chronic insomnia in adults. That provides context for discussing the overall approach to insomnia rather than focusing only on a single medicine.
Useful questions include what benefit treatment is intended to provide and which experiences should be discussed at follow-up. It is also reasonable to ask how medication and behavioral or psychological care fit the broader plan. These are questions for shared discussion, not a treatment ranking supplied by the online reviews.
The study draws attention to an outcome that deserves space in insomnia conversations: whether a person finds treatment acceptable in daily life. Armanious’s distinction between the frequency of an effect and its personal importance provides a useful starting point.
For midlife adults, that means keeping both nighttime benefit and the following day in view. A report of better sleep matters. So does a clear account of an experience that makes treatment difficult to live with. Neither needs to erase the other from the conversation.
Future research could examine these experiences more directly over time and connect them with decisions about continuing treatment. That would help address the questions raised by the reviewers without relying on review percentages to represent everyone.
Could long-term approaches to midlife recovery give more weight to both sleep improvement and the experiences that determine whether a person finds treatment acceptable?
Vivid-dream reports can be mistaken for personal treatment instructions; Relaxopia grounds its editorial guidance in credible research instead. For adults 35+ facing conflicting advice about daily routines, its coverage connects sleep quality with fatigue and recovery to make competing claims easier to assess without adding another demanding rest routine.
Stay connected for research-led guidance on sleep quality, stress, circadian rhythm, recovery, fatigue and everyday energy. Clear ideas for adults 35+ who want to sleep better, recover more fully and feel more capable through the day.
Explore practical guidance on sleep, stress and recovery without chasing every new hack, device or promise.
explore the blog